Inside the two way association between malignancy and alteration of haemostasis

• References

• 1 Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost 2001; 86: 395-403.
• 2 Heit JA, Silverstein MD, Mohr DN. et al The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86: 452-63.
• 3 Di Micco P, D’Uva M. To understand the two way clinical association between cancer and thrombophilia. Exp Oncol 2003; 25: 243-4.
• 4 Trousseau A. Phlegmasia alba dolens. In: Bailliere JB, Editor. Clinique Medicale de l’Hotel Dieu de Paris, 2 nd Ed. 1865; 3: 654-712.
• 5 Brenner B. Arterial thrombotic syndromes in cancer patients. Haemostasis 2001; 31 (Suppl. 01) 43-4.
• 6 Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol 2001; 106: 6-12.
• 7 Levi M. Cancer and DIC. Haemostasis 2001; 31 (Suppl. 01) 47-8.
• 8 Di Micco P, Niglio A, De Renzo A. et al Congenital and acquired thrombotic risk factors in lymphoma patients bearing upper extremities deep venous thrombosis: a preliminary report. J Transl Med 2004; 2: 7.
• 9 Monreal M, Raventos A, Lerma R. et al Pulmonary embolism in patients with upper extremity DVT associated to venous central lines. A prospective study. Thromb Haemost 1994; 72: 548-50.
• 10 Leone G, Sica S, Chiusolo P. et al Blood cells diseases and thrombosis. Haematologica 2001; 86: 1236-44.
• 11 Mamby CC, Love RR, Feizy JM. Protein S and Protein C level changes with adjuvant tamoxifen therapy in postmenopausal women. Breast Cancer Res Treat 1994; 30: 311-4.
• 12 Verheul HMW, Panigrahy D, Yuan J. et al Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. Br J Cancer 1999; 79: 114-8.
• 13 Rodeghiero F, Elice F. Thalidomide and thrombosis. Pathophysiol Haemost Thromb 2003; 33 (Suppl. 01) 15-18.
• 14 Falanga A. Tumor cell prothrombotic properties. Haemostasis 2001; 31 (Suppl. 01) 1-4.
• 15 Harbeck N, Kates RE, Gauger K. et al Urokinasetype plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost 2004; 91: 450-6.
• 16 Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 1999; 91: 22-36.
• 17 Varner JA, Nakada MT, Jordan RE. et al Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibody of c7E3 Fab (abciximab; ReoProTM). Angiogenesis 1999; 3: 53-60.
• 18 Verheul HM, Hoekman K, Luykx-de Bakker S. et al Platelets: transporter of vascular endothelial growth factor. Clin Cancer Res 1997; 3: 2187-90.
• 19 Rhee JS, Black M, Schubert U. et al The functional role of blood platelet components in angiogenesis. Thromb Haemost 2004; 92: 394-402.
• 20 Xu Y, Shen Z, Wiper DW. et al Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998; 280: 719-23.
• 21 Sorensen HT, Mellemkjaer L, Olsen JH. et al Prognosis of cancers associated to venous thromboembolism. N Engl J Med 2000; 343: 1846-50.
• 22 Sase T, Wada H, Yamaguchi M. et al Haemostatic abnormalities and thrombotic disorders in malignant lymphoma. Thromb Haemost 2005; 93: 156-62.
• 23 Perkins GD, McAuley DF, Davies S. et al Discrepancies between clinical and postmortem diagnoses in critically ill patients: an observational study. Critical Care 2003; 7: R129-R132.